Transgene SA - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of this page for potential risks for Transgene SA based on sector, geography and marketcap. The report of Transgene SA incorporates intelligence from across the internet as well as from public disclosures by Transgene SA. Other companies in the rating industry group for Transgene SA are shownin the table.
Transgene SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Transgene SA | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Transgene SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Transgene SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Transgene SA report the average age of the workforce?
Sign up for free to unlockDoes Transgene SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Transgene SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Transgene SA disclose cybersecurity risks?
Sign up for free to unlockDoes Transgene SA offer flexible work?
Sign up for free to unlockDoes Transgene SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Transgene SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Transgene SA conduct supply chain audits?
Sign up for free to unlockDoes Transgene SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Transgene SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Transgene SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Transgene SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Transgene SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Transgene SA disclose water use targets?
Sign up for free to unlockDoes Transgene SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Transgene SA have a product recall in the last two years?
Sign up for free to unlockDoes Transgene SA disclose incidents of discrimination?
Sign up for free to unlockDoes Transgene SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Transgene SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Transgene SA disclose parental leave metrics?
Sign up for free to unlockDoes Transgene SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Transgene SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Transgene SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Transgene SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Transgene SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Transgene SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Transgene SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Transgene SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Transgene SA disclose its waste policy?
Sign up for free to unlockDoes Transgene SA report according to TCFD requirements?
Sign up for free to unlockDoes Transgene SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Transgene SA disclose energy use targets?
Sign up for free to unlockDoes Transgene SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Transgene SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Transgene SA
These potential risks are based on the size, segment and geographies of the company.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.